|
|
| | 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate Basic information |
| Product Name: | 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate | | Synonyms: | 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate;3-[(AMinoiMinoMethyl)aMino]-4-Methylbenzoic acid ethyl ester Mon;Ethyl 3-guanidino-4-methylbenzoate nitrate;Ethyl 3-Carbamimidoylamino-4-methylbenzoate Nitrate;3-[(Aminoimethyl)amino]-4-methylbenzoic acid ethyl estermononitrate;((aminoiminomethyl)amino)-4-methylbenzoic acid ethyl ester mononitrate;ethyl 3-guanidino-4-methylbenzoate;3-(hydrazinylmethylideneamino)-4-methylbenzoic acid ethyl ester | | CAS: | 641569-96-2 | | MF: | C11H15N3O2.HNO3 | | MW: | 284.27 | | EINECS: | | | Product Categories: | | | Mol File: | 641569-96-2.mol | ![3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate Structure](CAS/GIF/641569-96-2.gif) |
| | 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate Chemical Properties |
| Melting point | 197.0 to 201.0 °C | | storage temp. | Sealed in dry,Room Temperature | | form | powder to crystal | | color | White to Almost white | | InChI | InChI=1S/C11H15N3O2.HNO3/c1-3-16-10(15)8-5-4-7(2)9(6-8)14-11(12)13;2-1(3)4/h4-6H,3H2,1-2H3,(H4,12,13,14);(H,2,3,4) | | InChIKey | YQMZYKJPGMVZJL-UHFFFAOYSA-N | | SMILES | C(C1C=C(C(C)=CC=1)NC(N)=N)(OCC)=O.[N+]([O-])(=O)O |
| | 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate Usage And Synthesis |
| Chemical Properties | 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate Appearance white to almost white powder to crystals, melting point 199 °C, storage 2-8 °C. | | Uses | 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate is an organic synthetic material or pharmaceutical intermediate compound that can be used in the preparation of N-phenyl-2-pyrimidinamine derivatives and in the synthesis of nilotinib and its salts. Nilotinib is a tyrosine kinase inhibitor used for the treatment of drug-resistant chronic myelogenous leukemia (CML), and in particular, for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients whose disease has progressed on or who cannot tolerate other therapies that included imatinib. Nilotinib is administrated as a hydrochloride salt in the form of capsules that are marketed in the USA and the EU under the name Tasigna. |
| | 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate Preparation Products And Raw materials |
|